Analysis: Mereo BioPharma - potential through takeovers and price rally

Analysis: Mereo BioPharma - potential through takeovers and price rally

According to a report by www.deraktionaer.de, Mereo BioPharma has recorded a share price increase of 200 percent since the end of April 2023. The AKTIONÄR's recommendation in issue 18/23 to acquire the biotech stock has proven to be successful, as the announced price target of 3.10 euros was achieved. Intraday on the Nasdaq, a transaction of 2.25 million shares was observed, followed by a new 52-week high at around $3.42 (3.14 euros). This development indicates high trading volume and strong demand for Mereo BioPharma shares.

The acquisition of Inhibrx by Sanofi for 1.7 billion dollars and the withdrawal of Amgen from a competing project for the treatment of osteogenesis imperfecta give Mereo BioPharma and its active ingredients such as setrusumab and alvelestat high potential. Despite the price increase, the company's market capitalization is comparatively low at only around $470 million. Due to these developments, THE SHAREHOLDER increases its price target to EUR 4.50.

These facts suggest that Mereo BioPharma could continue to show strong performance in the coming months based on market developments and the potential of its active ingredients. The takeovers and withdrawals of large pharmaceutical companies in similar projects show the interest and trust in Mereo BioPharma's products. It is expected that these developments will have a positive impact on the market, investors and the biotech industry as a whole.